Literature DB >> 6467147

Increasing the therapeutic response rates to anticancer drugs by applying the basic principles of pharmacology.

F M Schabel, D P Griswold, T H Corbett, W R Laster.   

Abstract

Mesh：

Substances：

Year:  1984        PMID： 6467147     DOI： 10.1002/1097-0142(19840915)54:1+<1160::aid-cncr2820541312>3.0.co;2-p

Source DB:  PubMed          Journal:  Cancer        ISSN： 0008-543X            Impact factor:   6.860


× No keyword cloud information.
  9 in total

Review 1.  Chemotherapy for Hodgkin's disease and aggressive non-Hodgkin's lymphoma. More is better, or is it?

Authors:  D J Dodwell; E S de Campos; J A Radford
Journal:  Drugs       Date:  1992-07       Impact factor: 9.546

2.  Intravesical chemotherapy: in vitro studies on the relationship between dose and cytotoxicity.

Authors:  M C Walker; J R Masters; C N Parris; P J Hepburn; P J English
Journal:  Urol Res       Date:  1986

3.  High dose chemotherapy with autologous stem cell rescue in adults with malignant primary brain tumors.

Authors:  L E Abrey; M K Rosenblum; E Papadopoulos; B H Childs; J L Finlay
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

4.  Factors causing dose variability in drug administration.

Authors:  R Demicheli; A Jirillo; G Bonciarelli; F Lonardi; M Pradella; M Balli
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Dose-intensive treatment of breast cancer supported by granulocyte-macrophage colony-stimulating factor (GM-CSF).

Authors:  J A Neidhart
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

6.  Intra-arterial chemotherapy with osmotic blood-brain barrier disruption for aggressive oligodendroglial tumors: results of a phase I study.

Authors:  Daniel J Guillaume; Nancy D Doolittle; Seymur Gahramanov; Nancy A Hedrick; Johnny B Delashaw; Edward A Neuwelt
Journal:  Neurosurgery       Date:  2010-01       Impact factor: 4.654

Review 7.  Dose intensity in cancer chemotherapy.

Authors:  D J Dodwell; H Gurney; N Thatcher
Journal:  Br J Cancer       Date:  1990-06       Impact factor: 7.640

8.  Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin.

Authors:  H P Hofs; D J Wagener; V De Valk-Bakker; H Van Rennes; D De Vos; W H Doesburg; H C Ottenheijm; W J De Grip
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

Review 9.  Chemotherapeutic dose intensification for treatment of malignant brain tumors: recent developments and future directions.

Authors:  Dale F Kraemer; David Fortin; Edward A Neuwelt
Journal:  Curr Neurol Neurosci Rep       Date:  2002-05       Impact factor: 6.030
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.